Skip to content
Loading...
SynAct Pharma logo
  • About
    • Management
    • Board of Directors
    • Advisory Board
    • History
    • Governance
      • General Meetings
      • Governance reports
      • Board Committees
      • Nomination Committee
      • Articles of Association
      • Auditor
    • Code of Conduct
    • Career
  • Our Science
    • Focus Areas
      • Autoimmune and Inflammatory Diseases
      • Host-Directed Therapy – Viral Infections
    • Our Medicines
      • Oral Drugs
      • Peptides
    • Synact Wiki
  • Diseases
    • Rheumatoid Arthritis
    • Nephrotic Syndrome
    • Polymyalgia Rheumatica
    • Dengue Fever
    • COVID-19
  • Development Program
    • Resomelagon
      • Inflammatory and Autoimmune Diseases
        • RA: The BEGIN Study
        • RA: The EXPAND Study
        • RA: The RESOLVE Study
        • RA: The ADVANCE Study
        • iMN: SynAct-CS003
      • Host-Directed Therapy in Viral Infections
        • COVID-19: RESOVIR-1
        • Dengue Fever: RESOVIR-2
    • TXP-11
  • Investors
    • Message from the CEO
    • Investment Highlights
    • Financial Reports
    • The Share
      • Share capital
    • Ownership Structure
    • Board and Management Holdings
    • Analysts
    • Presentations
    • Calendar
    • Prospectus and Rights Issues
  • News & Media
    • News and Press Releases
    • SynAct in the Media
    • Slide Decks and Presentations
    • Image Bank
  • ENG
  • SVE

News and Press Releases

Hero image
  • All releases
  • Regulatory
  • Non-regulatory
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • All years
December 9, 2016 - Non-regulatory

SynAct Pharma submits application for start of Phase I clinical study

November 28, 2016 - Non-regulatory

SynAct Pharma recruits specialists for the early clinical studies

November 4, 2016 - Non-regulatory

Interim report 3, 2016

October 28, 2016 - Non-regulatory

SynAct Pharma fulfilled its commitments to the financier Seed Fund CapNova by a one-time payment

August 31, 2016 - Non-regulatory

Half-yearly Report 2016

July 11, 2016 - Non-regulatory

Trading starts in SynAct Pharma AB’s shares and subscription options on Aktietorget today

July 4, 2016 - Non-regulatory

Market Announcement 174/16 – SynAct Pharma AB listed on Aktietorget 11 July 2016 – corrected version

June 14, 2016 - Non-regulatory

SynAct Pharma AB’s issue before listing oversubscribed

June 3, 2016

Publication of additional prospectus

May 30, 2016 - Non-regulatory

Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)

May 24, 2016 - Non-regulatory

Today the subscription period for SynAct Pharma AB’s issue opens, before the planned listing on Aktietorget

May 24, 2016

Publication of SynAct Pharma AB’s prospectus in connection with the issue ahead of planned listing on Aktietorget

May 12, 2016 - Non-regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

May 9, 2016 - Non-regulatory

Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)

April 21, 2016 - Non-regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

News & Media
  • News and Press Releases
  • SynAct in the Media
  • Slide Decks and Presentations
  • Image Bank

Download the latest company presentation

  • Company presentation - October 2025

SynactPharma-white

Advancing medicine trough
melanocortin activation

SynAct Pharma AB (publ)
Scheelevägen 2
SE-223 63 Lund
Sweden

Synact Pharma ApS
Dronninggårds Alle 136
2840 Holte
Denmark

  • About
  • Our Science
  • Diseases
  • Development Program
  • Investors
  • News & Media
  • Privacy Policy
  • Cookies
  • Get the latest news follow us on Linkedin

© 2025 SynAct Pharma AB. All right reserved.